Kinaxis Appoints Razat Gaurav as New CEO
8.1.2026 14:00:00 CET | Business Wire | Press release
With over two decades of supply chain experience and a proven record of driving global growth Razat Gaurav is uniquely positioned to lead Kinaxis in its next phase of AI-driven innovation.
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced the appointment of Razat Gaurav as Chief Executive Officer (CEO) effective January 12, 2026, his official start date, at which time he will also join the Kinaxis Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108330975/en/

Razat Gaurav, Kinaxis CEO
“After a rigorous search, the Board selected Razat to lead the company as CEO,” said Bob Courteau, Interim CEO and Board Chair at Kinaxis. “Razat’s twenty-five years of experience in supply chain solutions, his proven track record in advancing innovation-driven growth, and his passion for developing high-performing cultures make him uniquely qualified for this role. The Board looks forward to supporting Razat as he leads Kinaxis to the next phase of growth and success.”
Gaurav has an established track record of building and scaling global organizations in high-growth markets. He was the former CEO of both Planview and LLamasoft and previously held senior roles at Blue Yonder and i2 Technologies. He is also a board member at SPS Commerce, a publicly traded SaaS company helping businesses exchange data, automate processes, and run more efficient supply chains.
Since becoming CEO of Planview in 2021, Gaurav transformed the company’s AI journey, anchoring its mission to build the digital future of connected work. Under his leadership, Planview launched an enterprise-grade next-generation AI platform designed to harness the power of the latest emerging data architectures and multi-agent AI capabilities. This led to Planview more than doubling its revenue while maintaining high operating margins during his tenure.
"I’m excited to join the Kinaxis team and return to my roots in supply chain,” said Razat Gaurav, Chief Executive Officer. “Kinaxis is uniquely positioned to redefine the future of intelligent supply chains. Building on its rich legacy of concurrent planning, I will champion the next generation of AI-driven decision making and supply chain orchestration, using the Maestro platform. I appreciate the Board’s confidence and pledge to lead the company in setting new standards for innovation, building lasting partnerships and creating value for employees, customers and shareholders.”
This planned leadership transition reinforces Kinaxis’s commitment to creating sustainable long-term value for employees, customers, and shareholders. With this appointment, and other key leadership additions including Mark Morgan, President of Global Commercial, the executive team at Kinaxis is built to deliver sustained growth and lead the transformation of global supply chains.
Bob Courteau, Interim CEO, will now return to his role as non-executive Board Chair of Kinaxis. Given Courteau’s recent tenure in an executive role, Angel Mendez will continue as Independent Lead Director.
About Kinaxis
Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Cautionary Note and Forward-Looking Information
This news release contains forward-looking information within the meaning of Canadian securities legislation. Forward-looking information relates to future events or anticipated performance. This information is provided to help readers understand management’s beliefs, expectations, and opinions as at the date of this release and may not be suitable for other purposes. Forward-looking information in this news release includes statements regarding Kinaxis’ plans and prospects for growth, expansion, and innovation. Kinaxis’ actual performance may be materially different.
Forward-looking information is subject to a variety of risks and uncertainties which could cause actual events or results to differ including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated February 26, 2025 for its fiscal year ended December 31, 2024 and other risks identified in the Company’s filings with Canadian securities regulators available on SEDAR+ at https://www.sedarplus.ca. These risk factors are not exhaustive. The Company does not assume any obligation to update forward-looking information, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.
Source: Kinaxis Inc
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108330975/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom